Prostate Cancer RTOG 0924

Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Raduiotherapy in Unfavorable Intermediuate of Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Additional Information

Enrollment and Eligibility

Age: 18 years or older

Gender: Male

Disease: Pathologically proven diagnosis of prostate adenocarcinoma within 180 days of registration at moderate to high-risk for recurrence as determined by Gleason score, PSA, palpation and biopsies.

Study Phase: Phase III

Purpose: This randomized Phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer.

Robin Osborne at 270-688-1938